Ketamine for the Treatment of Opioid Use Disorder and Depression
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to examine whether an investigational medication called ketamine
is able to improve treatment outcomes for concurrent opioid addiction and depression when
used in conjunction with buprenorphine treatment. Study medications will be delivered twice
per week for four weeks. If you are eligible and you decide to enroll in the study, your
participation will last approximately 8 weeks, or 2 months.